Terence Kin-Wah Lee

List of Publications by Citations

105 papers	7,763 citations	49 h-index	87 g-index
112 ext. papers	8,908 ext. citations	8 avg, IF	5.65 L-index

#	Paper	IF	Citations
105	Identification and characterization of tumorigenic liver cancer stem/progenitor cells. *Gastroenterology*, **2007**, 132, 2542-56	13.3	991
104	CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. *Oncogene*, **2008**, 27, 1749-58	9.2	635
103	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. *Cell Stem Cell*, **2011**, 9, 50-63	18	463
102	Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. *Molecular Cancer Research*, **2008**, 6, 1146-53	6.6	383
101	Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. *Clinical Cancer Research*, **2006**, 12, 5369-76	12.9	333
100	miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. *Cell Stem Cell*, **2010**, 7, 694-707	18	331
99	Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. *Cell Reports*, **2016**, 15, 1175-89	10.6	183
98	Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. *Annals of Surgery*, **2003**, 237, 256-64	7.8	179
97	CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. *Hepatology*, **2012**, 55, 807-20	11.2	171
96	Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. *Hepatology*, **2014**, 60, 179-91	11.2	126
95	Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. *Hepatology*, **2016**, 64, 2062-2076	11.2	122
94	Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. *Cancer Chemotherapy and Pharmacology*, **2002**, 49, 78-86	3.5	113
93	Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. *Hepatology*, **2015**, 62, 534-45	11.2	103
92	Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. *Cancer Research*, **2007**, 67, 8800-9	10.1	97
91	Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases--activation of cell invasion and migration pathways. *Liver Transplantation*, **2007**, 13, 1669-77	4.5	95
90	PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. *Oncogene*, **2004**, 23, 4182-6	9.2	94
89	Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients. *Hepatology*, **2017**, 65, 1566-1580	11.2	93

88	Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. *Cancer Research*, **2006**, 66, 9948-56	10.1	91
87	Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. *Hepatology*, **2009**, 50, 1453-63	11.2	90
86	Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications. *Stem Cells International*, **2017**, 2017, 3714190	5	87
85	Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. *Oncogene*, **2002**, 21, 8498-505	9.2	85
84	SENP1 promotes hypoxia-induced cancer stemness by HIF-1 deSUMOylation and SENP1/HIF-1 positive feedback loop. *Gut*, **2017**, 66, 2149-2159	19.2	84
83	FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. *Clinical Cancer Research*, **2005**, 11, 8458-66	12.9	84
82	Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. *Hepatology*, **2011**, 53, 160-70	11.2	80
81	Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. *Molecular Cancer Therapeutics*, **2005**, 4, 1430-8	6.1	75
80	Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. *Journal of Hepatology*, **2017**, 67, 979-990	13.4	74
79	Attenuation of acute phase shear stress by somatostatin improves small-for-size liver graft survival. *Liver Transplantation*, **2006**, 12, 621-7	4.5	73
78	FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. *Carcinogenesis*, **2004**, 25, 2397-405	4.6	73
77	MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. *Cancer Research*, **2011**, 71, 583-92	10.1	71
76	Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. *British Journal of Cancer*, **2006**, 95, 1050-5	8.7	71
75	Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. *International Journal of Cancer*, **2011**, 128, 2182-91	7.5	69
74	FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. *American Journal of Transplantation*, **2005**, 5, 40-9	8.7	68
73	Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. *Journal of Biological Chemistry*, **2007**, 282, 33284-33294	5.4	66
72	Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. *Journal of Hepatology*, **2018**, 69, 826-839	13.4	64
71	Liver cancer stem cells: implications for a new therapeutic target. *Liver International*, **2009**, 29, 955-65	7.9	64

70	Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance. *Hepatology*, **2017**, 66, 1934-1951	11.2	62
69	Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. *Journal of Pathology*, **2012**, 226, 645-53	9.4	61
68	Distinct intragraft response pattern in relation to graft size in liver transplantation. *Transplantation* , **2003**, 75, 673-8	1.8	61
67	Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. *Oncotarget*, **2014**, 5, 5725-35	3.3	61
66	ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma. *Stem Cell Reports*, **2015**, 5, 45-59	8	58
65	Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/Ecatenin signaling. *Oncotarget*, **2016**, 7, 29371-86	3.3	58
64	Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. *Clinical Cancer Research*, **2006**, 12, 6910-9	12.9	56
63	FK 409 ameliorates small-for-size liver graft injury by attenuation of portal hypertension and down-regulation of Egr-1 pathway. *Annals of Surgery*, **2004**, 240, 159-68	7.8	56
62	Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. *Cancer Letters*, **2019**, 459, 176-185	9.9	55
61	Intragraft gene expression profiles by cDNA microarray in small-for-size liver grafts. *Liver Transplantation*, **2003**, 9, 425-32	4.5	53
60	PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. *Cell Reports*, **2018**, 25, 690-701.e8	10.6	53
59	The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. *British Journal of Cancer*, **2007**, 97, 50-7	8.7	52
58	An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. *Journal of Clinical Investigation*, **2011**, 121, 880-92	15.9	52
57	FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. *Cancer Letters*, **2006**, 233, 36-47	9.9	50
56	Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. *Cancer Letters*, **2013**, 338, 101-9	9.9	48
55	Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3. *Molecular Cancer Therapeutics*, **2017**, 16, 1531-1543	6.1	47
54	IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. *Cancer Research*, **2018**, 78, 2332-2342	10.1	43
53	Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. *Liver International*, **2016**, 36, 737-45	7.9	43

52	Fascin over-expression is associated with aggressiveness of oral squamous cell carcinoma. *Cancer Letters*, **2007**, 254, 308-15	9.9	43
51	Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. *Carcinogenesis*, **2003**, 24, 1729-36	4.6	41
50	Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. *Carcinogenesis*, **2005**, 26, 681-7	4.6	40
49	Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression. *Clinical Cancer Research*, **2006**, 12, 5082-9	12.9	39
48	Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. *Human Pathology*, **2007**, 38, 1201-6	3.7	39
47	CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation. *Hepatology*, **2020**, 71, 1279-1296	11.2	38
46	Attenuation of small-for-size liver graft injury by FTY720: significance of cell-survival Akt signaling pathway. *American Journal of Transplantation*, **2004**, 4, 1399-407	8.7	36
45	FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFB-BMP Signaling Cross-talk. *Cancer Research*, **2017**, 77, 5886-5899	10.1	35
44	Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1. *International Journal of Cancer*, **2010**, 127, 859-72	7.5	34
43	Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. *PLoS ONE*, **2011**, 6, e19804	3.7	33
42	Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma. *Hepatology*, **2020**, 72, 155-168	11.2	31
41	Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/Ecatenin pathway. *Cell Death and Differentiation*, **2018**, 25, 1426-1441	12.7	30
40	C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. *Oncotarget*, **2017**, 8, 23507-23516	3.3	28
39	TP53INP1 Downregulation Activates a p73-Dependent DUSP10/ERK Signaling Pathway to Promote Metastasis of Hepatocellular Carcinoma. *Cancer Research*, **2017**, 77, 4602-4612	10.1	27
38	Gene delivery using a receptor-mediated gene transfer system targeted to hepatocellular carcinoma cells. *International Journal of Cancer*, **2001**, 93, 393-400	7.5	27
37	Id-1 induces proteasome-dependent degradation of the HBX protein. *Journal of Molecular Biology*, **2008**, 382, 34-43	6.5	24
36	Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival. *American Journal of Transplantation*, **2006**, 6, 467-76	8.7	24
35	RhoE/ROCK2 regulates chemoresistance through NF-B/IL-6/ STAT3 signaling in hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 41445-41459	3.3	22

34	NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma. *Cancer Letters*, **2020**, 476, 48-56	9.9	20
33	The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. *Journal of Pathology*, **2017**, 243, 418-430	9.4	20
32	Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop. *Oncotarget*, **2016**, 7, 4939-48	3.3	18
31	Nidogen 1-Enriched Extracellular Vesicles Facilitate Extrahepatic Metastasis of Liver Cancer by Activating Pulmonary Fibroblasts to Secrete Tumor Necrosis Factor Receptor 1. *Advanced Science*, **2020**, 7, 2002157	13.6	18
30	The Pivotal Role of the Dysregulation of Cholesterol Homeostasis in Cancer: Implications for Therapeutic Targets. *Cancers*, **2020**, 12,	6.6	16
29	Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment. *Life Sciences*, **2002**, 70, 1677-90	6.8	16
28	Tie-2 regulates the stemness and metastatic properties of prostate cancer cells. *Oncotarget*, **2016**, 7, 2572-84	3.3	15
27	Rapamycin attenuates liver graft injury in cirrhotic recipient--the significance of down-regulation of Rho-ROCK-VEGF pathway. *American Journal of Transplantation*, **2006**, 6, 697-704	8.7	14
26	Insulin in UW solution exacerbates hepatic ischemia / reperfusion injury by energy depletion through the IRS-2 / SREBP-1c pathway. *Liver Transplantation*, **2004**, 10, 1173-82	4.5	14
25	Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. *Nature Reviews Gastroenterology and Hepatology*, **2021**,	24.2	13
24	Insulin in University of Wisconsin solution exacerbates the ischemic injury and decreases the graft survival rate in rat liver transplantation. *Transplantation*, **2003**, 76, 44-9	1.8	12
23	Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. *Oncology Reports*, **2004**, 12, 25-31	3.5	12
22	Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK. *BMC Complementary and Alternative Medicine*, **2014**, 14, 303	4.7	11
21	Deficiency in Embryonic Stem Cell Marker Reduced Expression 1 Activates Mitogen-Activated Protein Kinase Kinase 6-Dependent p38 Mitogen-Activated Protein Kinase Signaling to Drive Hepatocarcinogenesis. *Hepatology*, **2020**, 72, 183-197	11.2	11
20	EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma. *Cancer Research*, **2021**, 81, 3229-3240	10.1	11
19	RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. *Journal of Hepatology*, **2021**, 74, 360-371	13.4	11
18	Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 692940	5.7	10
17	Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. *Journal of Hepatology*, **2021**, 74, 838-849	13.4	10

List of Publications

16	Phosphorylation of nucleophosmin at threonine 234/237 is associated with HCC metastasis. *Oncotarget*, **2015**, 6, 43483-95	3.3	9
15	The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression. *Cell Death and Disease*, **2021**, 12, 148	9.8	9
14	Chemotherapy-Enriched THBS2-Deficient Cancer Stem Cells Drive Hepatocarcinogenesis through Matrix Softness Induced Histone H3 Modifications. *Advanced Science*, **2021**, 8, 2002483	13.6	9
13	Glucose deprivation-induced aberrant FUT1-mediated fucosylation drives cancer stemness in hepatocellular carcinoma. *Journal of Clinical Investigation*, **2021**, 131,	15.9	8
12	Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.. *Journal of Hepatology*, **2021**,	13.4	7
11	Dishevelled-3 phosphorylation is governed by HIPK2/PP1Cβ/ITCH axis and the non-phosphorylated form promotes cancer stemness via LGR5 in hepatocellular carcinoma. *Oncotarget*, **2017**, 8, 39430-39442	3.3	4
10	PRMT6 deficiency induces autophagy in hostile microenvironments of hepatocellular carcinoma tumors by regulating BAG5-associated HSC70 stability. *Cancer Letters*, **2021**, 501, 247-262	9.9	4
9	FSTL1 Secreted by Activated Fibroblasts Promotes Hepatocellular Carcinoma Metastasis and Stemness. *Cancer Research*, **2021**, 81, 5692-5705	10.1	4
8	Hampering Stromal Cells in the Tumor Microenvironment as a Therapeutic Strategy to Destem Cancer Stem Cells. *Cancers*, **2021**, 13,	6.6	3
7	Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma. *Journal of Pathology*, **2020**, 252, 65-76	9.4	2
6	Emerging role of fatty acid binding proteins in cancer pathogenesis. *Histology and Histopathology*, **2019**, 34, 1-12	1.4	2
5	Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer. *Cell Reports*, **2021**, 36, 109617	10.6	2
4	MAP9/ERCC3 signaling cascade: A new insight on understanding the chromosomal instability in hepatocellular carcinoma. *EBioMedicine*, **2020**, 54, 102709	8.8	1
3	Histone chaperone FACT complex coordinates with HIF to mediate an expeditious transcription program to adapt to poorly oxygenated cancers.. *Cell Reports*, **2022**, 38, 110304	10.6	1
2	Preclinical mouse models of hepatocellular carcinoma: An overview and update.. *Experimental Cell Research*, **2022**, 113042	4.2	1
1	Network-Pharmacology-Based Study on Active Phytochemicals and Molecular Mechanism of Cnidium monnieri in Treating Hepatocellular Carcinoma. *International Journal of Molecular Sciences*, **2022**, 23, 5400	6.3	0